Metafora https://validator.w3.org/feed/docs/rss2.html News Ressources METAglut1™ TEST Webinars Quality management system certification ISO 13485:2016 renewed METAglut1-fr Team Translating the regulatory landscape of medical devices to create fit-for-purpose artificial intelligence (AI) cytometry solutions Early patient access to health technologies: Is innovation needed for early management? Disruption of Glut1 in Hematopoietic Stem Cells Prevents Myelopoiesis and Enhanced Glucose Flux in Atheromatous Plaques of ApoE(-/-) Mice Prospective Multicenter Validation of a Simple Blood Test for the Diagnosis of Glut1 Deficiency Syndrome Usefulness of diagnostic tools in a GLUT1 deficiency syndrome patient with 2 inherited mutations A simple blood test expedites the diagnosis of glucose transporter type 1 deficiency syndrome Cell surface Glut1 levels distinguish human CD4 and CD8 T lymphocyte subsets with distinct effector functions Metabolic Reprogramming Supports IFN-γ Production by CD56bright NK Cells Cytostatic Effect of Repeated Exposure to Simvastatin: A Mechanism for Chronic Myotoxicity Revealed by the Use of Mesodermal Progenitors Derived from Human Pluripotent Stem Cells Results of our first study with AP-HP and the ICM on our innovative IVD test METAglut™ published in Annals of Neurology Testimonial from Dr. Domitille Gras on our innovative IVD test METAglut™ during World Health Day 2022 Coverage recommandation for our innovative IVD test METAglut™ by French National Authority for Health (HAS) Evaluation of our innovative IVD test METAglut™ published by French National Authority for Health (HAS) Alliance with Cerba HealthCare to advance metabolomics and drive diagnostic innovations Latest Findings on our Validation Study Announced at the European GLUT1D Conference Webinar Overview Strategic partnership with Sebia to develop innovative in vitro diagnostics Launch of our first innovative IVD test METAglut1™ to aid the diagnosis of Glut1DS developed with our partner CERBA HealthCare Webinar Quality management system certification ISO 13485:2016 obtained Inauguration meeting with our international scientific board of leading experts to enhance GLUT1DS diagnosis European regulatory approval successfully obtained for METAglut1™ our innovative IVD test for Glut1DS Attending the first European Conference on Glut1 Deficiency €3.2M Grant awarded: major boost for the launch of our validation study Company milestones shared at the Actionaria Event 2016 METAflow Raising awareness on rare diseases like Glut1DS at the annual meeting of EPNS 2023 Booth at the European Conference on Glut1 Deficiency 2018 Oral presentation on METAglut1™ our innovative IVD blood test at the meeting of SENP 2019 Booth to discuss latest results on METAglut1™ at the meeting of SENP 2018 Revealing key findings from our METAglut1™ validation study at the meeting of SENP 2022 Attending the 2019 Summit of the Glut1 Deficiency Foundation to talk about METAglut1™ our innovative IVD blood test Poster presentation on METAglut1™ our innovative IVD blood test at the meeting of SFNP 2019 Poster presentation on METAglut1™ our innovative IVD blood test at the meeting of SFNP 2022 New results on METAglut1™ validation study presented at the meeting of SFNP 2020 Updates at the European Conference on Glut1 Deficiency 2021 Company Strategy Vision Presented at the First International Biotechnology Meeting Introducing METAflow our innovative AI cytometry data analysis platform at ESCCA 2022 metabolism Attending the summit of the Glut1 Deficiency Foundation 2017 to talk about METAglut1™ our innovative IVD blood test Webinar Subscription Home